Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Platform Provides Consumers and Physicians with Data Needed to Make Informed Health Decisions on COVID-19

  • Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system.
  • The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the virus, thus allowing them to make informed health decisions
  • Aditxt’s platform is initially focusing on SARS-CoV-2, the virus that causes COVID-19, in recognition of the importance of immune monitoring and profiling in determining the course of action related to the virus. 

Though the COVID-19 pandemic is now in its third year, as noted in a recent Scientific American article (, scientists are still unsure whether there is a measure that could tell if people are protected from the virus. Still, different measures, collectively known as “correlates of protection,” define the immune response that a vaccine or viral infection would have to trigger to protect an individual from future infection. Two of these measures, neutralizing antibodies and T cells, are instrumental in immune profiling, a process that seeks to identify a person’s specific immune responses to the virus.  

And as a 2021 journal article discussing immune profiling of COVID-19 writes: “Variability in the host immune response is likely to play a major role in determining the course of SARS-CoV-2 infection. Given this, there is a need to apply immune profiling to better understand the interaction of this virus with the human immune system and how this influences clinical outcomes and informs vaccine development” (

Separately, Dr. Shivani Amdekar, a Medical Director at the Oxford Immune Algorithmics AI company, believes that deep immune monitoring – which involves measuring specialized immune cells – could be instrumental in advancing a test for long COVID. Moreover, the data collected from such initiatives, especially on a large scale, Dr. Shivani notes, could aid in uncovering potentially important relationships that may lead to useful therapeutic solutions for long COVID (

Aditxt (NASDAQ: ADTX), a biotech innovation company, understands this underlying value of immune monitoring and has continually worked to build awareness and visibility among consumers and healthcare providers of its AditxtScore(TM) Immune Monitoring Platform. With its inaugural focus being COVID-19, the platform creates comprehensive profiles of people’s immune systems, allowing them to understand, manage, and monitor their individual reactions to the virus. 

In addition, AditxtScore for COVID-19 provides timely reports on the immune status and vulnerability to the SARS-CoV-2 virus, providing consumers and their physicians with the data needed to make informed health decisions. 

AditxtScore(TM) is a timely technology amid warnings by the Biden administration that the U.S. could see 100 million COVID-19 infections and a potentially substantial wave of deaths this fall and winter. The government attributes this wave to emerging omicron subvariants that can escape the vaccines ( 

“In 2020, when the pandemic started, governments and public health agencies all over the world did everything possible to control infection. Infection status was the focus and, understandably so, to minimize the loss of lives,” Aditxt CEO and Founder Amro Albanna said in 2021 during a press conference in which the company announced it would open the AditxtScore(TM) Immune Monitoring Center in Richmond ( “As we move forward, we must transition from focusing on infection status to protection status. We need to understand our individual immunity status so we can make better decisions as we move forward.”

But Aditxt’s sights are also set on other maladies, as AditxtScore(TM) is being designed for other applications in infectious diseases, autoimmunity, and organ transplantation.  

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

For more information, visit the company’s websites at and

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050